-突变型非小细胞肺癌的肿瘤免疫微环境及其对治疗疗效的影响。 - Suppr

Suppr

超能文献

Tumor immune microenvironment of -mutant non-small-cell lung cancer and its impact on therapeutic efficacy.

作者信息

Matsumoto Yoshiya, Koh Yasuhiro

机构信息

Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Internal Medicine III, Wakayama Medical University, Wakayama, Japan.

出版信息

Immunotherapy. 2020 May;12(7):431-437. doi: 10.2217/imt-2019-0213. Epub 2020 Apr 22.

DOI:10.2217/imt-2019-0213

PMID:32316809

Abstract

摘要

相似文献

Tumor immune microenvironment of -mutant non-small-cell lung cancer and its impact on therapeutic efficacy.-突变型非小细胞肺癌的肿瘤免疫微环境及其对治疗疗效的影响。

Immunotherapy. 2020 May;12(7):431-437. doi: 10.2217/imt-2019-0213. Epub 2020 Apr 22.

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in Mutation-Positive Non-Small Cell Lung Cancer.表皮生长因子受体酪氨酸激酶抑制剂治疗对 EGFR 突变阳性非小细胞肺癌肿瘤免疫微环境的影响。

Clin Cancer Res. 2020 Apr 15;26(8):2037-2046. doi: 10.1158/1078-0432.CCR-19-2027. Epub 2020 Jan 14.

Immunotherapy in non-small cell lung cancer harbouring driver mutations.携带驱动基因突变的非小细胞肺癌的免疫治疗

Cancer Treat Rev. 2021 May;96:102179. doi: 10.1016/j.ctrv.2021.102179. Epub 2021 Mar 19.

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.动态肿瘤微环境在 EGFR 突变的非小细胞肺癌 (NSCLC) 免疫检查点抑制剂治疗争议中的作用。

Mol Cancer. 2019 Sep 16;18(1):139. doi: 10.1186/s12943-019-1062-7.

Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.肿瘤微环境对表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变型非小细胞肺癌疗效的影响。

Cancer Sci. 2019 Oct;110(10):3244-3254. doi: 10.1111/cas.14156. Epub 2019 Aug 30.

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.表皮生长因子受体突变型非小细胞肺癌的免疫检查点抑制剂：当前的争议和未来的方向。

Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.非小细胞肺癌中 EGFR 突变亚型与免疫检查点阻断治疗的反应。

Ann Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141.

[Application of Immune Checkpoint Inhibitors in EGFR Mutant  Advanced Non-small Cell Lung Cancer].免疫检查点抑制剂在表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌中的应用

Zhongguo Fei Ai Za Zhi. 2022 Sep 20;25(9):671-677. doi: 10.3779/j.issn.1009-3419.2022.102.32.

The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌在疾病初发时及酪氨酸激酶抑制剂治疗后的进展期的免疫特征

Immunotherapy. 2018 Sep;10(12):1041-1045. doi: 10.2217/imt-2018-0027.

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.表皮生长因子受体（EGFR）突变克隆和程序性死亡受体配体1（PD-L1）高表达克隆的异质性影响EGFR酪氨酸激酶抑制剂（EGFR-TKI）和程序性死亡受体1（PD-1）抑制剂的治疗效果。

Ann Oncol. 2018 Oct 1;29(10):2145-2147. doi: 10.1093/annonc/mdy312.

引用本文的文献

Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of Amplification: Implications for Novel Personalized Therapy.年轻患者口腔鳞状细胞癌的扩增率较高：对新型个性化治疗的启示。

Front Oncol. 2021 Nov 29;11:750852. doi: 10.3389/fonc.2021.750852. eCollection 2021.

Pembrolizumab Plus Chemotherapy or Anlotinib Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC.帕博利珠单抗联合化疗或安罗替尼与单独使用帕博利珠单抗治疗既往接受过治疗的表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）患者的疗效比较

Front Oncol. 2021 Apr 16;11:671228. doi: 10.3389/fonc.2021.671228. eCollection 2021.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验